Phase Iii Mariposa: Amivantamab + Lazertinib Vs Osimertinib In Egfr-Mutated Nsclc

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLC

MARIPOSA: longer-term follow-up of amivantamab & lazertinib in EGFR-m NSCLC

MARIPOSA: follow-up of lazertinib with amivantamab or osimertinib in EGFR-m NSCLC

MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinib

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2

European Society for Medical Oncology (ESMO)

Amivantamab and lazertinib in treatment-naïve EGFR-mutant NSCLC

MARIPOSA Update - Amivantamab + Lazertinib in 1L EGFR mutated metastatic NSCLC.

OncBrothers: Practice-Changing Cancer Discussions

PALOMA-3: subcutaneous vs intravenous amivantamab + lazertinib in refractory EGFR-mutated NSCLC

MARIPOSA: mechanisms of resistance to 1L amivantamab + lazertinib in pts with EGFR-m NSCLC

The future of amivantamab and lazertinib in EGFR-mutant NSCLC

Post-progression analysis of MARIPOSA-2: amivantamab + chemo in EGFR+ NSCLC

Amivantamab plus lazertinib is a new standard for EGFR-mutant NSCLC

Expert video report on amivantamab in combination therapy for 1L treatment in EGFRm, advanced NSCLC

European Society for Medical Oncology (ESMO)

Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC

PAPILLON Phase III primary results: amivantamab + chemo vs chemo in EGFR Exon 20 NSCLC

New Standard of care Treatment for EGFR Exon 20 Non-small cell Lung Cancer | Dr. Alexander Spira

OncBrothers: Practice-Changing Cancer Discussions

Q&A: What is the Efficacy of Amivantamab and Lazertinib? - Targeted Therapies in Lung Cancer 2023

GRACE - Global Resource for Advancing Cancer Education

Managing Amivantamab infusion reaction #2023 #oncology #lungcancer

OncBrothers: Practice-Changing Cancer Discussions

Amivantamab Plus Lazertinib for EGFR-Mutant Lung Cancer Following Progression on Osimertinib